Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials

Circulation - United States
doi 10.1161/circulationaha.106.620039
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Clinical Trials in Acute Heart Failure: Beginning of the End or End of the Beginning?

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2017English

High Risk of Fatal and Nonfatal Venous Thromboembolism in Myotonic Dystrophy

Circulation
Cardiovascular MedicinePhysiologyCardiology
2018English

Declining Rates of Fatal and Nonfatal Intracerebral Hemorrhage: Epidemiological Trends in Australia

Journal of the American Heart Association
Cardiovascular MedicineCardiology
2014English

Risk Scores in End Stage Heart Failure

Cardiologia Croatica
Cardiovascular MedicineCardiology
2014English

Letter by Hoglund and Nilsson Regarding Article, "Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure"

Circulation
Cardiovascular MedicinePhysiologyCardiology
2008English

Surrogate End Points for Clinical Trials of Kidney Disease Progression

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2006English

Clinical Trials, End Points, and Statistics—Measuring and Comparing Cancer Treatments in Practice

JAMA Oncology
Cancer ResearchOncology
2018English

Heart Failure Clinical Trials - Broadening the Definition of the Ideal Heart Failure Site Investigator

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2018English

Aldosterone, Hypertension and Heart Failure: Insights From Clinical Trials

Hypertension Research
Internal MedicineCardiovascular MedicinePhysiologyCardiology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy